摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

3,6-二苯基-3,4-二氢-2(1H)-嘧啶酮 | 34954-19-3

中文名称
3,6-二苯基-3,4-二氢-2(1H)-嘧啶酮
中文别名
——
英文名称
3,4-dihydro-3,6-diphenylpyrimidin-2(1H)-one
英文别名
2-Oxo-3,6-diphenyl-1,2,3,4-tetrahydropyrimidine;3,6-diphenyl-1,4-dihydropyrimidin-2-one
3,6-二苯基-3,4-二氢-2(1H)-嘧啶酮化学式
CAS
34954-19-3
化学式
C16H14N2O
mdl
——
分子量
250.3
InChiKey
CEYQVIHYILYSFU-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    490.1±45.0 °C(Predicted)
  • 密度:
    1.193±0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    2.7
  • 重原子数:
    19
  • 可旋转键数:
    2
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.06
  • 拓扑面积:
    32.3
  • 氢给体数:
    1
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2933599090

反应信息

  • 作为产物:
    描述:
    1-苯基-4-(1-苯基丙-2-烯基)-四唑-5-酮甲醇 为溶剂, 反应 5.0h, 以90%的产率得到3,6-二苯基-3,4-二氢-2(1H)-嘧啶酮
    参考文献:
    名称:
    3,4-二氢-6-取代的-3-苯基嘧啶-2(1 H)-ones的新型有效合成
    摘要:
    描述了一种合成3,4-二氢-6-取代的-3-苯基嘧啶-2(1 H)-ones的有吸引力且方便的新策略。 酒精溶液中4-烯丙基-四唑酮的光解(λ = 254 nm)以几乎定量的产率产生相应的嘧啶酮作为唯一产物,同时挤出分子氮。后处理程序包括在温和条件下在减压下简单蒸发溶剂。计算了4-烯丙基四唑酮的光解过程的反应热,表明所得产物的高稳定性。
    DOI:
    10.1016/j.tetlet.2005.07.101
点击查看最新优质反应信息

文献信息

  • Mechanistic Investigations into the Photochemistry of 4-Allyl-tetrazolones in Solution:  A New Approach to the Synthesis of 3,4-Dihydro-pyrimidinones
    作者:Luís M. T. Frija、Igor V. Khmelinskii、M. Lurdes S. Cristiano
    DOI:10.1021/jo060164j
    日期:2006.4.1
    Photolysis (λ = 254 nm) of 4-allyl-tetrazolones 2a−c was carried out in methanol, 1-propanol, 1-hexanol, acetonitrile, and cyclohexane. The sole primary photochemical process identified was molecular nitrogen elimination, with formation of pyrimidinones 6a−c. Following the primary photocleavage, secondary reactions were observed in acetonitrile and cyclohexane, leading to phenyl-isocyanate (7), aniline
    甲醇,1-丙醇1-己醇乙腈环己烷中进行4-烯丙基-四唑酮2a - c的光解(λ= 254 nm)。唯一确定的主要光化学过程是分子氮的消除,并形成嘧啶酮6a - c。一次光裂解后,在乙腈环己烷中观察到二次反应,生成异氰酸苯酯(7),苯胺(9)和1-苯基丙-1-烯基异氰酸酯(10a)。在酒精溶液中,主要产物6a - c,即使在延长的辐射下仍能保持光稳定性,从而有可能以很高的收率分离出作为稳定化合物的3,4-二氢嘧啶酮。嘧啶酮6a - c的观察到的光稳定性醇中的芳烃归因于通过可逆的质子转移引起的激发态猝灭,这归因于由于形成氢键而导致的溶剂笼稳定。醇的粘度与观察到的笼效应直接相关。4-烯丙基-四唑酮的光裂解可能导致笼中的三线态自由基对。溶剂粘度对光解量子产率的影响证实了这一假设。此外,溶解的分子氧会激发嘧啶酮的形成,正如三重态中间体所预期的那样,该中间体只能在T-S转化后形成产物分子,并被氧加速。
  • 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for gastrointestinal dysfunction
    申请人:——
    公开号:US20030206873A1
    公开(公告)日:2003-11-06
    A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount. The sensory nerve receptor agonist may be represented by the general formula 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 may be -hydroxy, -chloro, -fluoro, -alkyl, -acetoxy, -trifluoromethyl ; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention reduce pain, a sense of abdominal distension, tenesmus, and abnormal bowel function when formulated for oral delivery to human gastrointestinal tract and are useful to alleviate gastrointestinal dysfunction.
    提供了一种治疗组合物,它包含治疗有效量的 1-R1-苯基、4-R2-苯基取代的 1,2,3,6-四氢嘧啶-2-酮感觉神经受体激动剂。感觉神经受体激动剂可由通式 1-[R1-苯基]-4-[R2-苯基]-1,2,3,6-四氢嘧啶-2-酮表示 其中:R1可以是-羟基、-、-、-烷基、-乙酰氧基、-三甲基;R2是-硝基、-、-、-烷基、-三甲基。本发明的治疗组合物在配制成口服给药到人体胃肠道时,可减轻疼痛、腹胀感、胀气和肠道功能异常,有助于缓解胃肠功能紊乱。
  • 1,2,3,6-Tetrahydropyrimidine-2-one compositions, articles and therapeutic methods for upper airway breathing disorders
    申请人:——
    公开号:US20030206866A1
    公开(公告)日:2003-11-06
    A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one cold receptor agonist in a therapeutically effective amount. The cold receptor agonist may be represented by the general formula 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6 -tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, -fluoro, -alkyl, -acetoxy, -trifluoromethyl; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention when formulated for delivery to the mucous membranes of the nose and throat alleviate the sensations of airway obstruction and provide symptomatic relief of upper airway breathing disorders.
    提供了一种治疗组合物,它包含治疗有效量的 1-R1-苯基、4-R2-苯基取代的 1,2,3,6-四氢嘧啶-2-酮冷受体激动剂。冷受体激动剂可由通式 1-[R1-苯基]-4-[R2-苯基]-1,2,3,6-四氢嘧啶-2-酮表示 其中:R1为-羟基、-、-、-烷基、-乙酰氧基、-三甲基;R2为-硝基、-、-、-烷基、-三甲基。本发明的治疗组合物配制成给鼻腔和咽喉粘膜使用时,可减轻气道阻塞的感觉,缓解上气道呼吸障碍的症状。
  • Therapeutic 1,2,3,6-tetrahydropyrimidine-2-one compositions and methods therewith
    申请人:——
    公开号:US20030207851A1
    公开(公告)日:2003-11-06
    A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one cold receptor agonist in a therapeutically effective amount and preferably further comprises one or more pharmaceutically active drugs such as an anti-inflammatory glucocorticosteroid, a sympathomimetic amine decongestant, an anti-histamine, a local anesthetic, menthol or a menthol analog, and mixtures thereof. The cold receptor agonist may be represented by the general formula 1-[1R-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, -fluoro, -alkyl, -acetoxy, -trifluoromethyl; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention elicit long-lasting cooling or soothing, particularly when formulated for delivery to suppress the sensations of itch and pain, such as for delivery to inflamed skin, to the mucous membranes of the anogenital areas, and to the enteric mucosa.
    本发明提供了一种治疗组合物,该组合物包含治疗有效量的 1-R1-苯基、4-R2-苯基取代的 1,2,3,6-四氢嘧啶-2-酮冷受体激动剂,并优选进一步包含一种或多种药学活性药物,如抗炎性糖皮质激素、拟交感胺类减充血剂、抗组胺药、局麻药、薄荷醇或薄荷醇类似物及其混合物。冷受体激动剂可由通式 1-[1R-苯基]-4-[R2-苯基]-1,2,3,6-四氢嘧啶-2-酮表示,其中:R1为-羟基、-、-、-烷基、-乙酰氧基、-三甲基;R2为-硝基、-、-、-烷基、-三甲基。本发明的治疗组合物能产生持久的冷却或舒缓作用,特别是在配制成给药剂以抑制痒和痛的感觉时,如给发炎的皮肤、肛门生殖器部位的粘膜和肠道粘膜。
  • 1,2,3,6-tetrahydropyrimidine-2-one compositions and therapeutic methods therewith for pain and inflammation
    申请人:——
    公开号:US20030207904A1
    公开(公告)日:2003-11-06
    A therapeutic composition is provided that comprises a 1-R1-phenyl, 4-R2-phenyl substituted 1,2,3,6-tetrahydropyrimidine-2-one sensory nerve receptor agonist in a therapeutically effective amount. The sensory nerve receptor agonist may be represented by the general formula 1-[R1-phenyl]-4-[R2-phenyl]-1,2,3,6-tetrahydropyrimidine-2-one wherein: R1 is -hydroxy, -chloro, -fluoro, -alkyl, -acetoxy, -trifluoromethyl; and R2 is -nitro, -chloro, -fluoro, -alkyl, -trifluoromethyl. Therapeutic compositions of the invention reduce pain, itch, and a sense of discomfort, when formulated for topical delivery to the human lips, mouth, and to the anorectal area.
    提供了一种治疗组合物,它包含治疗有效量的 1-R1-苯基、4-R2-苯基取代的 1,2,3,6-四氢嘧啶-2-酮感觉神经受体激动剂。感觉神经受体激动剂可由通式 1-[R1-苯基]-4-[R2-苯基]-1,2,3,6-四氢嘧啶-2-酮表示 其中:R1为-羟基、-、-、-烷基、-乙酰氧基、-三甲基;R2为-硝基、-、-、-烷基、-三甲基。本发明的治疗组合物在配制成局部给药时,可减轻人体嘴唇、口腔和肛门直肠部位的疼痛、瘙痒和不适感。
查看更多